Department of Pediatrics, Asan Medical Center Children's Hospital, University of Ulsan College of Medicine, Seoul, Republic of Korea.
Mol Genet Metab. 2013 Jan;108(1):18-24. doi: 10.1016/j.ymgme.2012.11.011. Epub 2012 Nov 28.
Type 1 citrullinemia (CTLN1) often presents as a hyperammonemic encephalopathy in the neonatal period, but it can also develop in the late-infantile period and in adults. In addition, some patients can be identified in the presymptomatic period by neonatal or family member screening. In this study, twenty Korean patients with CTLN1 (19 families) were examined; fourteen patients with neonatal-onset, three with late-onset, and three that were identified presymptomatically. The 13 patients with hyperammonemic encephalopathy received continuous venovenous hemofiltration (CVVH) or peritoneal dialysis (PD). Although the hyperammonemia was relieved more effectively in the six patients on CVVH than the seven on PD, most of these patients suffered from severe neurologic deficits. Recurrent hyperammonemic episodes (7 pts, 35%), recurrent and reversible acute hepatic dysfunction (5 pts, 25%), and focal cerebral infarction (2 pts, 10%) were noted. The neonates with hyperammonemic encephalopathy had extensive brain injuries at the onset of hyperammonemia, followed by encephalomalacia and brain atrophy at quite an early age. Genetic testing for the ASS1 gene revealed a different mutation spectrum from those of other ethnicities; Three common mutations, c.421-2A>G (37.8%), c.1128-6_1188dup67 (18.9%), and p.Gly324Ser (16.2%), accounted for 73% of the mutations. The poor outcome was expected in patients with the peak ammonia level at onset over 600μmol/L, whose proportion was higher in the neonatal presentation group than in the presymptomatic/late presentation group. Our findings add to the current understanding of the ethnic diversity of CTLN1 from both clinical and genetic perspectives.
1 型瓜氨酸血症(CTLN1)常表现为新生儿期高氨血症性脑病,但也可在婴儿后期和成人期发病。此外,一些患者可通过新生儿或家庭成员筛查在症状前期被识别。本研究检查了 20 名韩国 CTLN1 患者(19 个家系);14 名新生儿发病,3 名晚发型,3 名症状前发病。13 名高氨血症性脑病患者接受了连续静脉-静脉血液滤过(CVVH)或腹膜透析(PD)治疗。尽管 6 名接受 CVVH 治疗的患者的高氨血症缓解更有效,但大多数患者都有严重的神经功能缺损。反复发生高氨血症发作(7 例,35%)、反复且可恢复的急性肝功能障碍(5 例,25%)和局灶性脑梗死(2 例,10%)。发生高氨血症性脑病的新生儿在高氨血症发作时即有广泛的脑损伤,随后在相当早的年龄出现脑软化和脑萎缩。ASS1 基因突变检测显示出与其他种族不同的突变谱;3 种常见突变,c.421-2A>G(37.8%)、c.1128-6_1188dup67(18.9%)和 p.Gly324Ser(16.2%),占突变的 73%。发病时氨峰值超过 600μmol/L 的患者预后较差,在新生儿起病组的比例高于症状前/晚发组。我们的研究结果从临床和遗传角度增加了对 CTLN1 种族多样性的认识。